Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
McKesson
Express Scripts
Moodys
Harvard Business School

Last Updated: November 13, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Tivantinib

See Plans and Pricing

« Back to Dashboard

What is the drug development status for Tivantinib?

Tivantinib is an investigational drug.

There have been 27 clinical trials for Tivantinib. The most recent clinical trial was a Phase 2 trial, which was initiated on November 1st 2010.

The most common disease conditions in clinical trials are Carcinoma, Lung Neoplasms, and Carcinoma, Hepatocellular. The leading clinical trial sponsors are National Cancer Institute (NCI), Daiichi Sankyo Inc., and ArQule.

There are nineteen US patents protecting this investigational drug and one hundred and thirty-six international patents.

Recent Clinical Trials for Tivantinib
TitleSponsorPhase
TIvantinib as Maintenance Treatment in Extended Small-cell Lung Cancer (TIMES)Istituto Oncologico Veneto IRCCSPhase 2
Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic ImpairmentMedpace, Inc.Phase 1
Pharmacokinetics of Tivantinib in Subjects With Advanced Solid Tumors and Hepatic ImpairmentDaiichi Sankyo Inc.Phase 1

See all Tivantinib clinical trials

Clinical Trial Summary for Tivantinib

Top disease conditions for Tivantinib
Top clinical trial sponsors for Tivantinib

See all Tivantinib clinical trials

US Patents for Tivantinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Tivantinib   Start Trial Combination therapy using c-Met inhibitor and IGF-1R inhibitor for c-Met inhibitor resistant cancers SAMSUNG ELECTRONICS CO., LTD. (Suwon-si, KR) YONSEI UNIVERSITY, UNIVERSITY-INDUSTRY FOUNDATION (UIF) (Seoul, KR)   Start Trial
Tivantinib   Start Trial Compositions and methods for treatment of cancer ArQule, Inc. (Woburn, MA)   Start Trial
Tivantinib   Start Trial Kinase inhibition models and their uses ArQule, Inc. (Woburn, MA)   Start Trial
Tivantinib   Start Trial Kinase inhibition models and their uses ArQule, Inc. (Woburn, MA)   Start Trial
Tivantinib   Start Trial Pyrrolidinone, pyrrolidine-2,5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer ArQule, Inc. (Woburn, MA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Tivantinib

Drugname Country Document Number Estimated Expiration Related US Patent
Tivantinib South Korea 20160061200 2034-11-21   Start Trial
Tivantinib Austria 486872 2025-02-09   Start Trial
Tivantinib Australia 2006213890 2025-02-09   Start Trial
Tivantinib Brazil PI0607240 2025-02-09   Start Trial
Tivantinib Canada 2599611 2025-02-09   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Mallinckrodt
McKinsey
McKesson
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.